Literature DB >> 26447940

Identification of Highly Promising Antioxidants/Neuroprotectants Based on Nucleoside 5'-Phosphorothioate Scaffold. Synthesis, Activity, and Mechanisms of Action.

Sagit Azran1, Ortal Danino1, Daniel Förster2, Sarah Kenigsberg1, Georg Reiser2, Mudit Dixit1, Vijay Singh1, Dan T Major1, Bilha Fischer1.   

Abstract

With a view to identify novel and biocompatible neuroprotectants, we designed nucleoside 5'-thiophosphate analogues, 6-11. We identified 2-SMe-ADP(α-S), 7A, as a most promising neuroprotectant. 7A reduced ROS production in PC12 cells under oxidizing conditions, IC50 of 0.08 vs 21 μM for ADP. Furthermore, 7A rescued primary neurons subjected to oxidation, EC50 of 0.04 vs 19 μM for ADP. 7A is a most potent P2Y1-R agonist, EC50 of 0.0026 μM. Activity of 7A in cells involved P2Y1/12-R as indicated by blocking P2Y12-R or P2Y1-R. Compound 7A inhibited Fenton reaction better than EDTA, IC50 of 37 vs 54 μM, due to radical scavenging, IC50 of 12.5 vs 30 μM for ADP, and Fe(II)-chelation, IC50 of 80 vs >200 μM for ADP (ferrozine assay). In addition, 7A was stable in human blood serum, t1/2 of 15 vs 1.5 h for ADP, and resisted hydrolysis by NPP1/3, 2-fold vs ADP. Hence, we propose 7A as a highly promising neuroprotectant.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26447940     DOI: 10.1021/acs.jmedchem.5b00575

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

Review 1.  Polypharmacology of conformationally locked methanocarba nucleosides.

Authors:  Kenneth A Jacobson; Dilip K Tosh; Kiran S Toti; Antonella Ciancetta
Journal:  Drug Discov Today       Date:  2017-08-03       Impact factor: 7.851

2.  Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology.

Authors:  Theodore E Liston; Sonja Hinz; Christa E Müller; Deborah M Holstein; Jay Wendling; Roger J Melton; Mary Campbell; William S Korinek; R Rama Suresh; Dane A Sethre-Hofstad; Zhan-Guo Gao; Dilip K Tosh; Kenneth A Jacobson; James D Lechleiter
Journal:  Purinergic Signal       Date:  2020-10-31       Impact factor: 3.765

3.  A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.

Authors:  Tali Fishman Jacob; Vijay Singh; Mudit Dixit; Tamar Ginsburg-Shmuel; Begoña Fonseca; Jesus Pintor; Moussa B H Youdim; Dan T Major; Orly Weinreb; Bilha Fischer
Journal:  Purinergic Signal       Date:  2018-07-17       Impact factor: 3.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.